Lisa Mandrusiak Authored 4th Most Read Article in U.S. via Mondaq Network
In September 2019, Lisa M. Mandrusiak came 4th as the contributor most read in United States with the article Thinking Outside The (Utility Patent) Box - Don't Overlook Design Patent Protection In The Life Sciences via the Mondaq distribution network.
Oblon Ajinomoto Litigation Team Receives Favorable Decision
Oblon obtained a favorable claim-construction result for its client, Ajinomoto Co., in the U.S. District Court for the District of Delaware. The underlying opinion determined that patent claims asserted by Kyowa Hakko Bio against Ajinomoto are indefinite.
The Flip Side of Reasonable Expectation of Success is Unpredictability
The Federal Circuit in a precedential opinion in Osai Pharmaceuticals, LLC v Apotex et al (Fed. Cir., October 4, 2019) http://www.cafc.uscourts.gov/sites/default/files/opinions-orders/18-1925.Opinion.10-4-2019.pdfreversed the USPTO's determination of obviousness in an IPR for patent claims directed to the treatment of non-small cell lung cancer (NSCLC). Just reading the background of the first three or four pages of the decision, it was already apparent that the Court was not going to be affirming the PTAB's decision. Notably:
Oblon is a sponsor of the SEBIO Investor & Partnering Forum 2019 that will be held on November 6-7th at The Biltmore in Miami-Coral Gables, Florida. The conference provides an unparalleled opportunity to meet key decision makers in the regional and national life science and medical technology communities. More than 300 biotech and medtech investors, corporate executives, university representatives, and entrepreneurs will attend this year.